Scopolamine detoxification technique for heroin dependence: A randomized trial

CNS Drugs

Volumn 27, Issue 12, 2013, Pages 1093-1102

  Liu, Sheng ^a   Li, Longhui ^b   Shen, Wenwen ^b   Shen, Xueyong ^a   Yang, Guodong ^b   Zhou, Wenhua ^b  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b NINGBO UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; METHADONE; NALOXONE; SCOPOLAMINE;

ADULT; ANESTHESIA; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DETOXIFICATION; DROWSINESS; DRUG DOSE REDUCTION; DSM-IV; FAINTNESS; FEMALE; FOLLOW UP; HEROIN DEPENDENCE; HOSPITAL CARE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; NERVOUSNESS; OPIATE ADDICTION; OUTPATIENT CARE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RESPIRATION DEPRESSION; SELF REPORT; SIDE EFFECT; SYMPTOM; THORAX PAIN; TREATMENT DURATION; URINALYSIS; VISUAL ANALOG SCALE; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; CHINA; FEMALE; FOLLOW-UP STUDIES; HEROIN DEPENDENCE; HUMANS; MALE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; SCOPOLAMINE HYDROBROMIDE; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 84890454646     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0111-9     Document Type: Article

References (41)

1. O' Connor PG. Methods of detoxification and their role in treating patients with opioid dependence. JAMA. 2005;294(8):961-3.
2. Amato L, Davoli M, Ferri M, Gowing L, Perucci CA. Effectiveness of interventions on opiate withdrawal treatment: an overview of systematic reviews. Drug Alcohol Depend. 2004;73(3):219-26.
3. Llorente del Pozo JM, Fernández Gómez C, Gutiérrez Fraile M, et al. Psychological and behavioural factors associated with relapse among heroin abusers treated in therapeutic communities. Addict Behav. 1998;23(2):155-69.
4. Kaplan HB, Meyerowitz JH. Social and psychological correlates of drug abuse: a comparison of addict and non-addict populations from perspective of self-theory. Soc Sci Med. 1970;4(2):203-25.
5. Heiwe S, Lonnquist I, Kallmen H. Potential risk factors associated with risk for drop-out and relapse during and following withdrawal of opioid prescription medication. Eur J Pain. 2011;15(9):966-70.
6. Sullivan MD, Edlund MJ, Zhang L, Unutzer J, Wells KB. Association between mental health disorders, problem drug use, and regular prescription opioid use. Arch Intern Med. 2006;166:2087-93.
7. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence. Arch Gen Psychiatry. 2006;63(2):210-8.
8. Zhang F, Zhou WH, Wang ZL, Yang GD. Effects of scopolamine on intravenous morphine self-administration and reinstatement of responding in rhesus monkeys. Chin J Clin Pharmacol Ther. 1998;3(2):99-102 (in Chinese).
9. See RE, McLaughlin J, Fuchs RA. Muscarinic receptor antagonism in the basolateral amygdala blocks acquisition of cocaine-stimulus association in a model of relapse to cocaine-seeking behavior in rats. Neuroscience. 2003;117(2):477-83.
10. Zhai H, Wu P, Chen S, Li F, Liu Y, Lu L. Effects of scopolamine and ketamine on reconsolidation of morphine conditioned place preference in rats. Behav Pharmacol. 2008;19(3):211-6.
11. Lu L, Xu NJ, Ge X, Yue W, Su WJ, Pei G, et al. Reactivation of morphine conditioned place preference by drug priming: role of environmental cues and sensitization. Psychopharmacology (Berl). 2002;159(2):125-32.
12. Itzhak Y, Martin JL. Scopolamine inhibits cocaine-conditioned but not unconditioned stimulant effects in mice. Psychopharmacology (Berl). 2000;152(2):216-23.
13. Rezayof A, Nazari-Serenjeh F, Zarrindast MR, Sepehri H, Delphi L. Morphine-induced place preference: involvement of cholinergic receptors of the ventral tegmental area. Eur J Pharmacol. 2007;562(1-2):92-102.
14. Basile AS, Fedorova I, Zapata A, Liu X, Shippenberg T, Duttaroy A, et al. Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia. Proc Natl Acad Sci USA. 2002;99(17):11452-7.
15. Thomsen M, Woldbye DP, Wortwein G, Fink-Jensen A, Wess J, Caine SB. Reduced cocaine self-administration in muscarinic M5 receptor-deficient mice. J Neurosci. 2005;25(36):8141-9.
16. Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry. 2006;63(10):1121-9.
17. Risch SC, Kalin NH, Janowsky DS. Cholinergic challenges in affective illness: behavioral and neuroendocrine correlates. J Clin Psychopharmacol. 1981;1(4):186-92.
18. Yang G, Xu K, Luo Q. Clinical study of scopolamine detoxification for the treatment of heroin addicts. Natl Med J China. 1996;76(2):141-4 (in Chinese).
19. Yang G, Zhou W, Xu K. The combined use of scopolamine, naltrexone and naloxone as a rapid, safe and effective detoxification treatment for heroin addicts. Natl Med J China. 1999;79(9):679-82 (in Chinese).
20. Jacobsen LK, Kosten TR. Naloxone challenge as a biological predictor of treatment outcome in opiate addicts. Am J Drug Alcohol Abuse. 1989;15(4):355-66.
21. Carroll KM, Rounsaville BJ, Keller DS. Relapse prevention strategies for the treatment of cocaine abuse. Am J Drug Alcohol Abuse. 1991;17(3):249-65.
22. Gossop M. The development of a Short Opiate Withdrawal Scale (SOWS). Addict Behav. 1990;15(5):487-90.
23. LaRowe SD, Myrick H, Hedden S, Mardikian P, Saladin M, McRae A, et al. Is cocaine desire reduced by N-acetylcysteine? Am J Psychiatry. 2007;164(7):1115-7.
24. Beck AT, Steer RA. Internal consistencies of the original and revised Beck Depression Inventory. J Clin Psychol. 1984;40(6):1365-7.
25. Zung WW. A rating instrument for anxiety disorders. Psychosomatics. 1971;12(6):371-9.
26. Liu XC. Factor analysis in SAS. Chin J Nervous Mental Dis. 1995;21(6):35-6 (in Chinese).
27. Wechsler D. Wechsler memory scale-revised. TX: Harcourt Brace Jovanovich; 1987.
28. Brickenkamp R. Test d2: Aufmerksamkeits-Belastungs-Test. Hogrefe: Handanweisungen; 1994.
29. Tang Y, Liu ZM. Relapse and recovery in drug abuse. Chin J Drug Depend. 2008;17(6):402-5 (in Chinese).
30. Sun B, Ye Y, Qin L. An analysis of relapse factors of 615 Chinese heroin addicts. Chin J Drug Depend. 2001;10(3):214-6 (in Chinese).
31. Liu Z, Cao J, Zhu GR. Epidemiological study on the relapse of Chinese opiate addicts. Chin Bull Drug Depend. 1997;6(3):169-74 (in Chinese).
32. Hiller ML, Knight K, Simpson DD. Risk factors that predict drop-out from corrections-based treatment for drug abuse. Prison J. 1999;79(4):411-30.
33. Broers B, Giner F, Dumont P, Mino A. In-patient opiate detoxification in Geneva: follow-up at 1 and 6 months. Drug Alcohol Depend. 2000;58(1-2):85-92.
34. Smyth BP, Barry J, Lane A, Cotter M, O'Neill M, Quinn C, et al. Inpatient treatment of opiate dependence: medium term follow-up outcomes. Br J Psychiatry. 2005;187:360-5.
35. Ghodse AH, Reynolds M, Baldacchino AM, Dunmore E, Byrne S, Oyefeso A, et al. Treating an opiate-dependent inpatient population: a one-year follow-up study of treatment completers and noncompleters. Addict Behav. 2002;27(5):765-78.
36. Xiang XH, Wang HL, Wu WR, Guo Y, Cao DY, Wang HS, et al. Ethological analysis of scopolamine treatment or pretreatment in morphine dependent rats. Physiol Behav. 2006;88(1-2):183-90.
37. Glasper A, Gossop M, de Wet C, Reed L, Bearn J. Influence of the dose on the severity of opiate withdrawal symptoms during methadone detoxification. Pharmacology. 2008;81(2):92-6.
38. Riley AL, Pournaghash S. The effects of chronic morphine on the generalization of buprenorphine stimulus control: an assessment of kappa antagonist activity. Pharmacol Biochem Behav. 1996;52(4):779-87.
39. Collins ED, Kleber HD, Whittington RA, Heitler NE. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. JAMA. 2005;294(8):903-13.
40. Harvey RD. Muscarinic receptor agonists and antagonists: effects on cardiovascular function. Handb Exp Pharmacol. 2012;208:299-316.
41. Drevets WC, Furey ML. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry. 2010;67(5):432-8.